Leveraging our AAV vector engineering and process development expertise, we unlock gene therapy's curative promise for incurable diseases, reaching far more patients.
We advance the delivery efficiency and therapeutic performance of AAV gene therapy, while offering practical and systematic solution to overcome the key technical and clinical limitations inherent to current AAV strategies.
Building on this foundation, GluGene Therapeutics aims to establish differentiated vector design strategies and to develop next-generation AAV gene therapies capable of transforming the treatment paradigm for intractable diseases. Harnessing precision engineering and AI to pioneer AAV gene therapies and unlock bespoke therapeutic solutions Evolutionary Linkage to
Gene TherapyATLASDesigning precision gene therapy vectors through high-resolution AAV variant mapping01AIMINGOptimizing vector targeting through AI and precision engineering 02GRADETranslating optimized vector designs into clinically applicable therapeutics03ATLASHigh-Throughput Screening Meets
Functional MappingATLAS (AAV Targeting through Library-driven Advanced Selection) is an experimental-based, high-resolution vector performance mapping technology that quantitatively evaluates AAV delivery efficiency across diverse biological contexts and routes of administration.
By systematically visualizing and exploring multiple design pathways, ATLAS enables structured navigation of the design space toward defined gene therapy objectives.
Through library-based screening, ATLAS establishes a comprehensive mapping and selection framework that identifies promising AAV vector candidates while defining the evolutionary landscape of vector performance.
This framework provides a robust starting point for subsequent strategic vector design and optimization. AIMINGOptimizing vector targeting through AI and precision engineering GRADETranslating optimized vector designs into clinically applicable therapeutics02ATLASDesigning precision gene therapy vectors through high-resolution AAV variant mapping0103AIMINGAI-Driven Vector OptimizationAIMING (AI-Mediated, Innovative, and de-Novo Gene) vector engineering technology is an AI-driven vector optimization module that learns from multidimensional experimental data accumulated through ATLAS.
By integrating biological and physicochemical constraints, AIMING predicts optimal delivery routes and vector design strategies that account for diverse biological barriers.
By deriving design directions that achieve the highest performance within specific biological environments and disease contexts, AIMING precisely narrows the exploration space of vector engineering and maximizes development efficiency.
Through AI-based analysis combined with innovative engineering, AIMING simultaneously enhances vector accuracy, efficiency, and safety while minimizing off-target risk, enabling the practical implementation of personalized gene therapy. ATLASDesigning precision gene therapy vectors through high-resolution AAV variant mapping01AIMINGOptimizing vector targeting through AI and precision engineering 02GRADETranslating optimized vector designs into clinically applicable therapeutics03GRADEScalable GMP Manufacturing &
Process DevelopmentGRADE (GMP-Ready AAV Design and Engineering) technology is a GMP-compatible process and manufacturing platform that translates optimized AAV vector designs into clinically applicable therapeutics.
By introducing statistical Design of Experiments (DoE) methodologies from the earliest design stages, GRADE quantitatively identifies critical process parameters and their interactions, enabling optimization of manufacturing processes that ensure reproducibility, scalability, and safety in compliance with GMP standards.
Through this approach, GRADE enables industrial-scale production and rigorous quality control of precisely engineered AAV vectors, bridging research-stage innovation to real therapeutic solutions for patients. ATLASDesigning precision gene therapy vectors through high-resolution AAV variant mapping01AIMINGOptimizing vector targeting through AI and precision engineering 02GRADETranslating optimized vector designs into clinically applicable therapeutics03The integrated ATLAS-AIMING-GRADE platform extends beyond a conventional vector design tool
—it is an evolution-based platform that understands, predicts, and optimizes complex biological environments.
Conventional AAV development approaches rely on single selection pressures under limited conditions, resulting in a structural limitation that confines performance improvements to local maxima.
GluGene Therapeutics derives vector performance at the global maxima level—beyond local maxima—by systematically expanding the exploration space and minimizing design bias through sequential and parallel evolutionary strategies that apply multiple selection pressures in stages.
Based on this integrated framework, GluGene Therapeutics present the most rational and scientifically grounded development pathway toward clinically reproducible gene therapies with simultaneously validated accuracy, safety, and efficiency.ATLAS-AIMING-GRADEarrow_upwardarrow_downward0{{current_slide_index}}
—
0{{total_slide_count}}
